Abstract
Purpose
To explore the prevalence of synchronous and metachronous tonsillar cancer in patients with base of tongue cancer, as well as identifying potential risk factors linked to these secondary malignancies. We aim to answer the following question: Should bilateral tonsillectomy be recommended to patients diagnosed with base of tongue cancer?
Methods
A case-series study was conducted at Aarhus University Hospital, including all patients with histologically confirmed base of tongue squamous cell carcinoma treated between January 2012 and December 2021. Data from electronic patient records, including diagnosis of prior, synchronous or metachronous tonsillar cancer, demographics, and clinical features were analysed. Fisher’s exact test was performed to assess factors associated with synchronous and metachronous tonsillar cancer.
Results
Among 198 patients with base of tongue cancer, 5.6% had a history of tonsillar cancer, either prior to (4.5%), synchronous (0.5%), or metachronous (0.5%) to the base of tongue diagnosis. The prevalence of synchronous or metachronous tonsillar cancer among patients without previous bilateral tonsillectomy was 1.2%. Patients with tonsillar cancer were older, had heavier smoking histories, and exhibited less frequent P16-overexpression.
Conclusion
Our findings deepen understanding of tonsillar cancer in patients with base of tongue cancer. The prevalence of synchronous or metachronous tonsillar cancer was found to be relatively low, suggesting that routine tonsillectomy for all base of tongue cancer patients is not warranted.
Keywords: Base of tongue, Head and neck cancer, Carcinoma, Malignancy, Secondary cancer, Cancer
Introduction
The risk of developing a second primary malignancy is increased in patients with head and neck cancer [1, 2]. These malignancies may manifest either synchronous (diagnosed either at the same time as the primary lesion or within six months) or metachronous (more than six months after the primary cancer). Occurrence of secondary primary malignancies constitute major clinical issues as they impact patients prognosis negatively; indeed, these malignancies are one of the leading causes of death in patients with head and neck cancer [3]. In newly diagnosed head and neck cancer patients, the occurrence of synchronous malignancies is estimated to be in the range 1–6%, while metachronous malignancies occur in almost one third of patients [4–7].
As such, it has long been recognised that individuals with head and neck squamous cell carcinoma face an increased susceptibility to developing second primary malignancies. Only few studies have, however, investigated the locations and specific risks associated with synchronous and metachronous second primary malignancies across the spectrum of head and neck subsites, including patients with base of tongue cancer [8–10]. Although base of tongue cancer, a subset of oropharyngeal malignancies, is garnering increasing attention due to its rising incidence and complex clinical nature, the prevalence and characteristics of synchronous and metachronous tonsillar cancer in these patients remain unexplored [11].
It is important to identify the risk profile linked to these secondary malignancies in patients with base of tongue cancer to enhance patient counselling, improve management, and better guidance in the planning of follow-up. Given that bilateral tonsillar cancer is relatively common, we hypothesised that the frequency of tonsillar cancer would also be considerable among patients with base of tongue cancer [12]. We undertook the current study to explore the prevalence of synchronous and metachronous tonsillar cancer in patients with base of tongue cancer to answer the following question: Should bilateral tonsillectomy be recommended to patients diagnosed with base of tongue cancer? In addition, we aimed to characterise patients with base of tongue cancer with or without associated tonsillar cancer.
Methods
The study was approved by the Danish Data Protection Agency (1-16-02-94-22) and the Danish Safety Authority (1-45-70-42-22). The requirement for informed consent was waived given the nature of the study.
Study population
This is a case-series, including all patients with histologically confirmed base of tongue squamous cell carcinoma (DC019) treated at the Department of Otorhinolaryngology, Head and Neck Surgery, Aarhus University Hospital. The study period was from January 1st 2012 until December 31st 2021.
Data sources
We examined the medical records of all patients using the electronic patient journal. A standardized extraction form was made, including age, sex, clinical symptoms, treatment modalities, tobacco history, alcohol consumption, prior, synchronous and metachronous tonsillar cancer, and histological reports.
Outcomes
Our main outcome was the occurrence of synchronous or metachronous tonsillar cancer (DC09*) in patients with base of tongue squamous cell carcinoma. In addition, we decided to include patients with tonsillar cancer prior to the index cancer in the description of patients with both base of tongue and tonsillar cancer. We defined synchronous cancer as those diagnosed either at the same time as the index-cancer or within six months, metachronous cancer as those diagnosed more than six months after the index-cancer, and previous cancer as those diagnosed prior to the index-cancer. Secondary outcomes were factors potentially associated with prior, synchronous and metachronous tonsillar cancer. These were analysed for trends and associations.
Statistical analyses
Continuous variables were reported as means or medians and SD. Comparisons of means were performed by unpaired t-test. Categorical variables were summarised by percentages or frequencies. Comparisons of categorical baseline characteristics between patient groups were performed by the Fisher’s exact test. The normality of data was assessed using quantile-quantile plots. Statistical significances were defined as a p value < 0.05. All analyses were performed using Stata 15 (StataCorp LP, TX).
Results
Patient characteristics
A total of 198 patients with histologically confirmed base of tongue squamous cell carcinoma were included in this study. Patient characteristics are summarized in Table 1. Among cases, the mean age was 62 years (range 41–83) and 140 (71%) patients were males. Ninety (46%) patients were active tobacco smokers at the time of diagnosis. The quantitative volume of smoking (in pack years) was available in 118 (60%) patients. No significant differences in patient characteristics were observed between males and females. 18% (36/198) of patients had a history of bilateral tonsillectomy.
Table 1.
Characteristics of patients with base of tongue squamous cell carcinoma
| Cases n = 198 |
|
|---|---|
| Males, n (%) | 140 (71%) |
| Age, mean years (SD) | 62.1 (8.3) |
| P16-overexpression, n (%) 1 | 126/188 (67%) |
| Tonsillar cancer, n (%) | 11 (5.6%) |
| Prior to BOT, n | 9 |
| Synchronous, n | 1 |
| Metachronous, after BOT, n | 1 |
| Tobacco smoking | |
| Current, n (%) | 90 (46%) |
| Previous, n (%) | 57 (29%) |
| Never, n (%) | 51 (26%) |
| Pack years, mean2 (SD) | 40 (20) |
| Alcohol abuse3, n (%) | 60 (30%) |
| Follow up, months, median (range) | 37.6 (0.2–104) |
BOT = Base of tongue
1 P16 status was unavailable in 10 (5.1%) patient cases
2 For previous and current smokers
3 Defined as > 14 units per week for > 1 year
The median follow-up time was 3.1 years (range: 0.2–8.7). P16-overexpression was noted in the histology reports in 126 (64%) patients, while 62 (31%) tumours were p16-negative, and P16-status was unknown in the remaining 10 (5%) cases. P16 overexpression was significantly more frequent among non-smoking patients (49/51, 96%) compared to former or current smokers (40/77, 52%) (p < 0.001).
Prevalence of previous, synchronous and metachronous tonsillar cancer
Tonsillar cancer was diagnosed in 11 (5.6%) cases, either prior to base of tongue diagnosis (n = 9, 4.5%), synchronous (n = 1, 0.5%) or metachronous (n = 1, 0.5%) (Table 2). The prevalence of synchronous or metachronous tonsillar cancer among base of tongue cancer patients without previous bilateral tonsillectomy (n = 162) was 1.2%. In the nine patients with tonsillar cancer prior to base of tongue cancer, the median time between the two cancers was 8.7 years (range: 4.5–17.6).
Table 2.
Comparison of patients diagnosed with base of tongue cancer with and without associated tonsillar cancer
| Tonsillar cancer | |||
|---|---|---|---|
| Yes | No | p-value | |
| Tonsillar cancer, n (%) | 11 (6%) | 187 (94%) | |
| Prior to BOT cancer, n (%) | 9 (4.5%) | ||
| Synchronous, n (%) | 1 (0.5%) | ||
| Metachronous, n (%) | 1 (0.5%) | ||
| Males, n (%) | 6 (55%) | 134 (72%) | 0.30 |
| Age, mean years (SD) | 69.0 (5.0) | 61.7 (8.3) | 0.005 |
| P16-overexpression, n (%) | 3 (27%) | 123 (69%)1 | 0.006 |
| Tobacco smoking, n (%) | |||
| Current | 5 (46%) | 85 (45%) | 1.0 |
| Previous | 5 (46%) | 52 (28%) | 0.30 |
| Never | 1 (9%) | 50 (27%) | 0.29 |
| Pack years, mean2 (SD) | 53 (15) | 38 (20) | 0.021 |
| Excessive alcohol consumption3, n (%) | 5 (45%) | 55 (29%) | 0.31 |
| Follow up, median months (range) | 21 (0.2–63) | 39 (0.5–104) | 0.049 |
BOT = Base of tongue
1 P16 status was unavailable in 10 (5.05%) patient cases
2 For previous and current smokers
3 Defined as > 14 units per week for > 1 year
Factors associated with previous, synchronous and metachronous tonsillar cancer
Compared to patients without associated tonsillar cancer, patients diagnosed with previous, metachronous or synchronous tonsillar cancer were older (mean 69.0 vs. 61.7 years, p = 0.005), those that were smokers (current or previous) had a heavier smoking load (53 vs. 38 pack years, p = 0.021), and the tumour exhibited less frequently P16-overexpression (27% vs. 69%, p = 0.006) (Table 2). The patient with synchronous tonsillar cancer was a 59-years old former smoker (37 pack years) and a P16-positiv tumour, whereas the patient with metachronous cancer (36 months after the index cancer) was 70-years old and actively smoker (45 pack years) and a P16-negative tumour.
Treatment modality
89% (177/198) of patients received curatively intended treatment, either chemo-radiotherapy (n = 96, 49%), radiotherapy (n = 62, 31%), or surgical resection (n = 24, 12%). Palliative care was chosen in 21 (11%) cases. The one BOT cancer patient with synchronous tonsillar cancer received curatively intended radiotherapy whereas the patient with metachronous tonsillar cancer received curatively intended chemo-radiotherapy. Among patients with a tonsillar cancer prior to their BOT cancer, five received chemo-radiotherapy and four received radiotherapy as treatment for their primary tonsillar cancer (all curatively intended).
Discussion
To our knowledge, the current study is the first to estimate the prevalence of synchronous and metachronous tonsillar cancer among patients with base of tongue cancer. We examined the prevalence of synchronous and metachronous tonsillar cancer among patients with base of tongue cancer covering a follow-up period of up to 9 years. In total, 1.0% (2/198) of patients with base of tongue cancer were diagnosed with synchronous and metachronous tonsillar cancer. Deducting the 36 patients with previous bilaterally tonsillectomy, 1.2% (2/162) of patients at risk for developing secondary tonsillar cancer did so in the follow up period. With an aim to describe the full association between base of tongue and tonsillar cancer, and thus including the nine patients with tonsillar cancer prior to base of tongue cancer, 5.6% (11/198) of patients with base of tongue cancer were diagnosed with tonsillar cancer. In this latter cohort, patients were older age, those that were smokers had increased tobacco consumption, and P16 positivity were less prevalent compared to base of tongue cancer patients without associated tonsillar cancer.
The occurrence of simultaneous second primary cancers in individuals with head and neck cancer has previously been found in the range 1–6% [5, 13–15]. Our data demonstrate that approximately 1 in 20 patients with base of tongue cancer have had or developed associated tonsillar malignancy, with only two of the cases occurring after the index cancer (mean follow up 37.6 months). The vast majority of previous studies investigating the prevalence of synchronous cancer in patients with oropharyngeal cancer have focused on patients with primary tonsillar cancer or they did not differentiate between subsites [16]. Several studies suggests that patients who develop second primary malignancy within the oropharynx are more prone to having initial tonsil cancer and developing their second primary in the contralateral tonsil [9, 12, 17]. Only few researchers have addressed the occurrence of second primary among patients with base of tongue cancer, and they focused on HPV-positive cases treated with transoral robotic surgery [9, 18]. Though not estimating the prevalence, Strober et al. recently concluded, that the tonsils are the most common site for secondary malignancies in patients with HPV-positive base of tongue cancer [9]. Stepan et al. found that base of tongue cancer was the most frequent index cancer among patients, who developed secondary oropharyngeal malignancy, demonstrating that 1.2% (5/412) of patients with oropharyngeal cancer developed secondary tonsillar cancer. Unfortunately, a prevalence and patient characteristics of synchronous and metachronous tonsillar cancer in patients with base of tongue cancer was not provided [18].
In our cohort of 162 patients, who were not bilaterally tonsillectomized at time of base of tongue diagnosis, only two patients (1.2%) developed tonsillar cancer, suggesting that the risk of a secondary tonsillar cancer in bases of tongue cancer patients is low. This prevalence is likely to be somewhat underestimated with a median follow-up time of 3.1 years, with regards to the fact that the mean time from tonsillar cancer to secondary base of tongue cancer diagnosis was 8.7 years in our cohort.
Overall, individuals with head and neck squamous cell carcinoma face significantly increased risk of developing second primary malignancy. This increased risk is associated to both patient and tumor characteristics. In our study, older age, tobacco load, and P16-negative tumor was significantly associated with dual (both base of tongue and tonsillar) malignancy. These findings are in line with previous studies finding lower risk of simultaneous second primary malignancy among non-smoking patients with HPV-positive oropharyngeal cancer [10, 19]. Indeed, recent studies suggest that patients with HPV-positive oropharyngeal cancer exhibit the lowest risk of simultaneous second primary malignancies among all head and neck cancer patients [19–21]. Although all patients with dual malignancies in the present study received either chemo-radiotherapy or radiotherapy, our study is underpowered to conclude on the effects of different treatment modalities concerning the occurrence of secondary primaries. Even with higher numbers, the results would likely be biased because cases with advanced disease are not suitable for surgical treatment.
Limitations
While informative, our study has limitations to consider. Firstly, reliance solely on medical records for data collection may have resulted in incomplete or inaccurate information due to inconsistent documentation. Secondly, distinguishing second primary from recurrence is challenging. An experienced consultant reviewed all relevant records and scans to differentiate between second primaries from recurrences. With only one case of metachronous tonsillar cancer diagnosed 3 years after base of tongue cancer and a mean time of 8.7 years (and a minimum of 3.5 years) between prior tonsillar cancer and base of tongue cancer, we believe that the risk of falsely categorizing patients as having second primary is very little. Lastly, statistical power may be insufficient for detecting smaller associations, and our study period may not have allowed adequate follow-up for certain outcomes.
Conclusion
Our study found that 1.2% of patients with base of tongue cancer without previous tonsillectomy developed synchronous or metachronous tonsillar cancer, rising to 5.6% when including those with prior tonsillar cancer. Patients with both cancers (regardless of temporal relation) were older, had heavier smoking histories, and showed less frequent P16-overexpression. Based on our findings, we do not recommend tonsillectomy for all patients diagnosed with a base of tongue cancer.
Funding
Open access funding provided by Aarhus University Hospital. This work received no specific grant from any funding agency.
Open access funding provided by Aarhus University Hospital
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Declarations
Conflict of interest
The authors declare that there is no conflict of interest.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Chuang SC, Scelo G, Tonita JM et al (2008) Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer 123:2390–2396. 10.1002/ijc.23798 [DOI] [PubMed] [Google Scholar]
- 2.Jérémie Jégu F, Binder-Foucard C, Borel M, Velten (2013) Trends over three decades of the risk of second primary cancer among patients with head and neck cancer. Oral Oncol 49(1):9–14. 10.1016/j.oraloncology.2012.06.018 [DOI] [PubMed] [Google Scholar]
- 3.Baxi SS, Pinheiro LC, Patil SM, Pfister DG, Oeffinger KC, Elkin EB (2014) Causes of death in long-term survivors of head and neck cancer. Cancer 120(10):1507–1513. 10.1002/cncr.28588Epub 2014 Feb 22. PMID: 24863390 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.León X, Del Prado Venegas M, Orús C, Kolañczak K, García J, Quer M (2005) Metachronous second primary tumours in the aerodigestive tract in patients with early stage head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 262(11):905–909 [DOI] [PubMed] [Google Scholar]
- 5.Sturgis EM, Miller RH (1995) Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol 104:946–954 [DOI] [PubMed] [Google Scholar]
- 6.Jones AS, Morar P, Phillips DE et al (1995) Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 75:1343–1353 [DOI] [PubMed] [Google Scholar]
- 7.Panosetti E, Luboinski B, Mamelle G et al (1989) Multiple synchronous and metachronous cancers of the upper aerodigestive tract: a 9-year study. Laryngoscope 99:1267–1273 [DOI] [PubMed] [Google Scholar]
- 8.Schwartz LH, Ozsahin M, Zhang GN et al (1994) Synchronous and metachronous head and neck carcinomas, Cancer, vol. 74, no. 7, pp. 1933–1938 [DOI] [PubMed]
- 9.Strober W, Shishido S, Wood B, Lewis JS Jr, Kuhs K, Ferris RL, Faden DL (2020) Two for the price of one: prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck cancers. Oral Oncol 100:104475. 10.1016/j.oralonco [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Stepan K et al (2022) Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma. Head Neck 44(5):1069–1078 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Mourad M, Jetmore T, Jategaonkar AA, Moubayed S, Moshier E, Urken ML (2017) Epidemiological trends of Head and Neck Cancer in the United States: a SEER Population Study. J Oral Maxillofac Surg 75(12):2562–2572 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Rokkjaer MS, Klug TE (2018) Prevalence of synchronous bilateral tonsil squamous cell carcinoma: a retrospective study. Clin Otolaryngol 43(1):1–6 [DOI] [PubMed] [Google Scholar]
- 13.Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6(5):963–968. 10.1002/1097-0142(195309)6:5%3C963::aid-cncr2820060515%3E3.0.co;2-q [DOI] [PubMed] [Google Scholar]
- 14.Leon X, Quer M, Diez S, Orús C, opez-Pousa L, Burgués A (1999) Second neoplasm in patients with head and neck cancer. Head Neck 21:204–210. 10.1002/(SICI)1097-0347(199905)21 [DOI] [PubMed] [Google Scholar]
- 15.Morris LG, Sikora AG, Hayes RB et al (2011) Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer. Cancer Causes Control 22:671–679 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Bollig CA, Lee DS, Mazul AL, Stepan K, Puram SV, Massa ST, Zenga J, Faden DL, Doering MM, Jackson RS, Pipkorn P (2021) Systematic review of second primary Oropharyngeal cancers in patients with p16 + Oropharyngeal Cancer. Otolaryngol Head Neck Surg 164(4):733–740. 10.1177/0194599820951175 [DOI] [PubMed] [Google Scholar]
- 17.Dziegielewski PT, Boyce BJ, Old M et al (2017) Transoral robotic surgery for tonsillar cancer: addressing the contralateral tonsil. Head Neck 39:2224–2231 [DOI] [PubMed] [Google Scholar]
- 18.Stepan K, Craig E, Skillington SA et al (2022) Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma. Head Neck 44(5):1069–1078. 10.1002/hed.27002PMID: 35175648; PMCID: PMC9112335 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Jain KS, Sikora AG, Baxi SS, Morris LGT (2013) Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer, Cancer. 119(10):1832–1837 [DOI] [PubMed]
- 20.Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, McHugh JB, Urba SG, Stoerker J, Walline HM, Kurnit DM, Cordell KG, Davis SJ, Ward PD, Bradford CR, Carey TE (2010) Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 16(4):1226–1235. 10.1158/1078-0432.CCR-09-2350 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. ;29(32):4294 – 301. 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3. Corrected and republished in: J Clin Oncol. 2023;41(17):3081–3088. PMID: 21969503
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.